ArticleThe Journal of veterinary medical science2025
In vitro susceptibility testing of essential oils and their main components against antifungal-resistant Malassezia pachydermatis.
Article in The Journal of veterinary medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antifungal Effects ofPathogens (Basel, Switzerland) · 2026Article
- In Vitro Antifungal Activity of Essential Oils and Nanoemulsions ofAntibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canine Malassezia dermatitis (CMD) and otitis externa are generally treated by antifungal drugs. However, azole-resistant strains have been isolated from canine skin and ear canals worldwide. Phytochemicals isolated from essential oils are effective alternatives for inhibiting Malassezia pachydermatis. To evaluate the usefulness of phytochemicals against azole-resistant isolates, we performed in vitro susceptibility testing using the phytochemicals carvacrol, citral, and thymol. Eight antifungal-resistant isolates were obtained from 7 cases of dermatitis and 1 case of otitis externa during 2022 and 2023 from dogs in Tokyo and Kanagawa, Japan. Fungal susceptibility to carvacrol, citral, and thymol were assessed using the modified broth microdilution method. The minimum inhibitory concentrations (MICs) of the phytochemicals in all isolates were as follows: 0.03 to 0.125% for carvacrol; 0.03 to 0.125% for thymol; and 0.03% to 0.125% for citral. Based on these results, carvacrol, citral, and thymol appear to be effective against azole-resistant strains. The phytochemicals appear to be effective for treating antifungal-resistant cases of CMD and otitis externa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.